<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01459016</url>
  </required_header>
  <id_info>
    <org_study_id>14162</org_study_id>
    <secondary_id>I4O-MC-BACH</secondary_id>
    <nct_id>NCT01459016</nct_id>
  </id_info>
  <brief_title>A Non-drug Methods Study in Participants With Alzheimer's Disease</brief_title>
  <official_title>An Exploratory Study of Brain Imaging Biomarkers in Patients With Alzheimer's Pathology Receiving Standard of Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the volume, function and composition of the brain using magnetic
      resonance imaging (MRI) and positron emission tomography (PET) scanning technology in
      participants with memory complaints or early signs of Alzheimer's pathology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After trial initiation, the protocol was amended to extend the single observation time period
      (6 to 9 months) to two time points (6 and 12 months), and to focus on prodromal AD
      (Mini-Mental State Examination [MMSE] 23-30 inclusive, Free and Cued Selective Reminding Test
      [FCSRT] less than or equal to [≤] 24 for free recall or ≤ 44 for total recall). Participants
      enrolled under the original protocol were allowed to continue in the extension study if they
      so desired, and if they met the new inclusion criteria. Due to the number of participants
      that completed the extended trial, no sub-group analysis was performed based on which
      amendment the participants entered under.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI)</measure>
    <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
    <description>BBSI and VBSI were calculated based on the voxel-wise difference between co-registered baseline and follow-up scans. Least squares (LS) mean value was controlled for baseline value and visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Hippocampus Volume Average Percent (%) Change (Chg)</measure>
    <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
    <description>Automated hippocampal volumetry was performed using the Learning Embeddings for Atlas Propagation (LEAP) algorithm. LS mean value was controlled for baseline value and visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI)</measure>
    <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
    <description>Distributed functional connectivity in selected brain networks was calculated from the rsfMRI scans. Values were derived from low-frequency (0.01-0.1 hertz [Hz]) temporal correlations between different regions over the approximately 6-minute rsfMRI time series scan. Distributed measures of functional connectivity were calculated as the mean Pearson correlation between the average low-frequency time courses in predefined sets of regions of interest (ROI) within the default mode network (DMN), salience network (SN) and sensorimotor networks (SMN). LS mean value was controlled for baseline value and visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA)</measure>
    <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
    <description>DTI scans used FA to measure water diffusion directionality in selected white matter (WM) tracts. ROI: Corpus collosum (CC), internal capsule (IC), posterior cingulum bundle (PCB), temporal white matter (TWM), uncinate fasciculus (UF), superior longitudinal fasciculus (SLF). LS mean value was controlled for baseline value and visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD)</measure>
    <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
    <description>DTI scans used MD to measure the overall magnitude of water diffusion in selected WM tracts, without specific regard to directionality. ROI: CC, IC, PCB, TWM, UF, SLF. LS mean value was controlled for baseline value and visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline Brain Amyloid Load Using Positron Emission Tomography (PET) and Florbetapir</measure>
    <time_frame>Baseline</time_frame>
    <description>Composite summary standardized uptake value ratio (SUVR) normalized to mean whole cerebellum. Regions used for composite summary were posterior cingulum, anterior cingulum, parietal cortex, lateral temporal cortex and frontal cortex.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Vasogenic Edema on MRI Scan at a Field Strength of 3 Tesla (3T)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Microhemorrhage on MRI Scan at a Field Strength of 3T</measure>
    <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mini Mental State Examination (MMSE) Total Score</measure>
    <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
    <description>The MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30; lower score indicates greater disease severity. LS mean value was controlled for baseline value and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Alzheimer's Disease Assessment Scale Extended Cognitive Subscale (ADAS-Cog14) Total Score</measure>
    <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
    <description>The ADAS-Cog14 is the ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. LS mean value was controlled for baseline value and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Clinical Dementia Rating (CDR) Total Score</measure>
    <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
    <description>The CDR is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score ranges from 0 to 18. Higher scores indicate greater disease severity. LS mean value was controlled for baseline value and visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Imaging Biomarkers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PET scan using florbetapir</intervention_name>
    <description>A single intravenous microdose of 260 MBq (7 mCi) 18F-AV-45 (florbetapir F 18) will be administered.</description>
    <arm_group_label>Imaging Biomarkers</arm_group_label>
    <other_name>AV-45</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI Scan</intervention_name>
    <description>Three different measurements will be taken: volumetric MRI (vMRI), diffusion tensor imaging (DTI), and resting state functional MRI (rsfMRI). In addition, radiological MRI scans will be taken to monitor vasogenic edema and microhemorrhages.</description>
    <arm_group_label>Imaging Biomarkers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Present with prodromal Alzheimer's Disease (AD) or mild AD based on the disease
             diagnostic criteria

          -  Are men or post-menopausal women, at least 55 years of age. Post-menopausal women are
             defined as women who have had a hysterectomy and/or bilateral oophorectomy; or who
             have been amenorrheic for at least 2 years

          -  Have a caretaker/study informant who provides a separate written informed consent to
             participate. If a caretaker/study informant cannot continue, one replacement is
             allowed

          -  Gradual and progressive change in memory function reported by participants or
             informants over more than 6 months

          -  Objective evidence of significantly impaired episodic memory characteristic of
             hippocampal dysfunction on testing: Free and Cued Selective Reminding Test (FCSRT):
             less than or equal to (≤) 16 for free recall or ≤ 40 for total recall. Protocol
             amendment: FCSRT ≤ 24 for free recall or ≤ 44 for total recall

          -  Clinical Dementia Rating (CDR) equals 0.5 or 1, Memory box score greater than or equal
             to 0.5

          -  Mini Mental Scale Examination (MMSE) 20-30. Protocol amendment: MMSE 23-30, inclusive

          -  Positive florbetapir F 18 scan

          -  Participants must meet all of the Disease Diagnostic Criteria to be considered for
             enrollment

        Exclusion Criteria:

          -  Diagnosis or history of other possible etiology of dementia, including but not limited
             to other neurodegenerative disorders

          -  Frontotemporal dementia, Lewy body disease, vascular dementia, Huntington's Disease or
             concomitant Parkinson's disease, progressive supranuclear palsy (PSNP) or other
             movement disorder

          -  Has B12 &lt;200 pg/L or folate &lt;7.5 nmol/L indicating vitamin deficiency

          -  Has a history within the past 5 years of a serious infectious disease affecting the
             brain, including meningitis, or encephalitis

          -  Significant history of alcoholism or substance abuse (at the judgment of the
             investigator)

          -  Severe or recurrent head injury that is clinically relevant to the disease under
             study, (that is, with permanent neurological/cognitive sequelae)

          -  Onset of dementia following heart surgery or cardiac arrest

          -  Diagnosis or history of cerebrovascular disease (for example, stroke, transient
             ischemic attack), severe carotid stenosis, cerebral hemorrhage, intracranial tumor,
             subarachnoid hemorrhage, or subdural hematoma that could contribute to the subject's
             current cognitive or functional status, impair ability to fully participate in the
             trial or that may impact status

          -  Has had a Positron Emission Tomography (PET) within 6 months of the scheduled imaging
             follow-up

          -  Greater than 4 cerebral microhemorrhages (CMH) on T2* -weighted gradient-recalled echo
             sequences (regardless of their anatomical or diagnostic characterization as &quot;possible&quot;
             or &quot;definite&quot;), a single area of superficial siderosis, or prior evidence of
             macrohemorrhage

          -  Any indications of severe deep white matter lesions or vasogenic edema that present as
             hyperintense regions on the Fluid Attenuated Inversion Recovery (FLAIR) sequence, or
             other clinically relevant findings observed on the Magnetic Resonance Imaging (MRI)
             scans

          -  Specific exclusionary brain MRI findings, as determined by the investigator in
             consultation with the sponsor, that could either contribute to the participant's
             current cognitive or functional decline impair ability to fully participate in the
             trial or that may impact status during the trial (for example, brain tumors or other
             non-vascular structural abnormalities like hydrocephalus)

          -  History within the past 5 years of a primary or recurrent malignant disease with the
             exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma,
             cervical carcinoma in situ, or in situ prostate cancer with a normal prostate-specific
             antigen (PSA) post resection

          -  History of clinically significant cardiovascular or renal events

          -  Diastolic blood pressure of 95 or more and systolic blood pressure of 160 or more in
             sitting position after at least 5 minutes of rest

          -  Any history of seizure

          -  History of clinically significant head trauma or clinically significant unexplained
             loss of consciousness within the last 5 years (as determined by the investigator in
             consultation with the Sponsor)

          -  A current Axis I diagnosis of major depressive disorder or other psychiatric illness
             (Diagnostic and Statistical Manual Revised Fourth Edition [DSM-IV-TR]) criteria per
             the investigator's judgment. (Note: Participants on a stable antidepressant and/or
             anxiolytic treatment may participate.)

          -  Having suicidal ideations, or attempted suicide in the past 15 years

          -  History of schizophrenia, bipolar disorder, or other severe mental illness

          -  Known history of alcohol or drug abuse (as defined by the DSM-IV-TR) within 5 years
             prior to enrolling or a positive result regarding use of illicit drugs on the drug
             screening test

          -  Chronic hepatic diseases as indicated by liver function test abnormalities (alanine
             trasaminase [ALT], aspartate transaminase [AST], bilirubin, or gamma-glutamyl
             transferase [GGT] above 2 times upper limit of normal), positive serology for
             Hepatitis B or C, or other manifestations of liver disease

          -  Has compromised renal function at screening, as determined by creatinine clearance &lt;30
             mL/min based on Cockcroft-Gault calculation of creatinine clearance

          -  History of asthma, chronic obstructive pulmonary disease, or other chronic respiratory
             conditions

          -  Known positive human immunodeficiency virus (HIV) status, history of syphilitic
             infection

          -  A clinically significant abnormality in the 12-lead electrocardiograms (ECG),
             including complete heart block, bradycardia (heart rate &lt;50 beats/minute), tachycardia
             (heart rate ≥95 beats/minute), sinus pauses &gt;2 seconds, second or third degree heart
             block, QTc &gt;450 msec for males or QTc &gt;470 for females

          -  Treatment with an investigational small molecule within 1 year preceding the first
             study period, or participation in a trial with active or passive immunization against
             amyloid if participant was assigned to the active treatment arm

          -  Fulfillment of any contraindications to a 3T magnetic resonance imaging (MRI) scan
             (for example, subjects with non-removable ferromagnetic implants (such as cardiac
             pacemaker), aneurysm clips or other foreign bodies, or subjects with claustrophobic
             symptoms that would contraindicate an MRI scan)

          -  Sensitivity to florbetapir F 18

          -  Are not capable of swallowing whole oral medications

          -  Abnormal thyroid function

               -  Thyroid stimulating hormone (TSH) values are outside of the normal range 0.3-5.6
                  mIU/L. (NOTE: Participants with stable treatment of hypothyroidism and with
                  normal value of TSH will be allowed to enter the study)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri, 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cahors</city>
        <zip>46005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Castres</city>
        <zip>81108</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Foix Cedex</city>
        <zip>09017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lavaur</city>
        <zip>BP85 81502</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Léon</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montauban Cedex</city>
        <zip>82013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vic-En-Bigorre</city>
        <zip>65500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2011</study_first_submitted>
  <study_first_submitted_qc>October 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2011</study_first_posted>
  <results_first_submitted>December 21, 2016</results_first_submitted>
  <results_first_submitted_qc>December 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2017</results_first_posted>
  <last_update_submitted>December 21, 2016</last_update_submitted>
  <last_update_submitted_qc>December 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Brain Imaging Biomarkers</keyword>
  <keyword>Magnetic resonance imaging biomarker</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care</title>
          <description>Participants with prodromal to mild Alzheimer’s Disease (AD) underwent a florbetapir F 18 positron emission tomography (PET) scan. (Single intravenous microdose of 260 to 370 megabecquerels (MBq) [7 to 10 millicuries (mCi)] of florbetapir.) Those who tested amyloid positive and met other entry criteria received standard of care for up to 12 months (mos). No therapeutic investigational drug intended to treat AD was administered.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Amendment Discontinuation Criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who enrolled in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care</title>
          <description>Participants with prodromal to mild AD underwent a florbetapir F 18 PET scan. (Single intravenous microdose of 260 to 370 MBq [7 to 10 mCi] of florbetapir.) Those who tested amyloid positive and met other disease diagnostic criteria received standard of care for up to 12 mos. No therapeutic investigational drug intended to treat AD was administered.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.2" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI)</title>
        <description>BBSI and VBSI were calculated based on the voxel-wise difference between co-registered baseline and follow-up scans. Least squares (LS) mean value was controlled for baseline value and visit.</description>
        <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
        <population>All participants who enrolled in the study and had an evaluable MRI at the designated time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Participants with prodromal to mild AD underwent a florbetapir F 18 PET scan. (Single intravenous microdose of 260 to 370 MBq [7 to 10 mCi] of florbetapir.) Those who tested amyloid positive and met other disease diagnostic criteria received standard of care for up to 12 mos. No therapeutic investigational drug intended to treat AD was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI)</title>
          <description>BBSI and VBSI were calculated based on the voxel-wise difference between co-registered baseline and follow-up scans. Least squares (LS) mean value was controlled for baseline value and visit.</description>
          <population>All participants who enrolled in the study and had an evaluable MRI at the designated time point.</population>
          <units>milliliters (mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BBSI - 6 Mos (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.349" lower_limit="3.735" upper_limit="8.963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BBSI - 12 Mos (n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.663" lower_limit="8.608" upper_limit="14.719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VBSI - 6 Mos (n=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.016" lower_limit="1.361" upper_limit="2.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VBSI - 12 Mos (n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.196" lower_limit="3.088" upper_limit="5.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Hippocampus Volume Average Percent (%) Change (Chg)</title>
        <description>Automated hippocampal volumetry was performed using the Learning Embeddings for Atlas Propagation (LEAP) algorithm. LS mean value was controlled for baseline value and visit.</description>
        <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
        <population>All participants who enrolled in the study and had an evaluable MRI at the designated time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Participants with prodromal to mild AD underwent a florbetapir F 18 PET scan. (Single intravenous microdose of 260 to 370 MBq [7 to 10 mCi] of florbetapir.) Those who tested amyloid positive and met other disease diagnostic criteria received standard of care for up to 12 mos. No therapeutic investigational drug intended to treat AD was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Hippocampus Volume Average Percent (%) Change (Chg)</title>
          <description>Automated hippocampal volumetry was performed using the Learning Embeddings for Atlas Propagation (LEAP) algorithm. LS mean value was controlled for baseline value and visit.</description>
          <population>All participants who enrolled in the study and had an evaluable MRI at the designated time point.</population>
          <units>percentage of hippocampus volume average</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hippocampus Volume Average % Chg - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.693" lower_limit="-2.273" upper_limit="-1.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hippocampus Volume Average % Chg - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.057" lower_limit="-3.884" upper_limit="-2.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI)</title>
        <description>Distributed functional connectivity in selected brain networks was calculated from the rsfMRI scans. Values were derived from low-frequency (0.01-0.1 hertz [Hz]) temporal correlations between different regions over the approximately 6-minute rsfMRI time series scan. Distributed measures of functional connectivity were calculated as the mean Pearson correlation between the average low-frequency time courses in predefined sets of regions of interest (ROI) within the default mode network (DMN), salience network (SN) and sensorimotor networks (SMN). LS mean value was controlled for baseline value and visit.</description>
        <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
        <population>All participants who enrolled in the study and had an evaluable MRI at the designated time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Participants with prodromal to mild AD underwent a florbetapir F 18 PET scan. (Single intravenous microdose of 260 to 370 MBq [7 to 10 mCi] of florbetapir.) Those who tested amyloid positive and met other disease diagnostic criteria received standard of care for up to 12 mos. No therapeutic investigational drug intended to treat AD was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI)</title>
          <description>Distributed functional connectivity in selected brain networks was calculated from the rsfMRI scans. Values were derived from low-frequency (0.01-0.1 hertz [Hz]) temporal correlations between different regions over the approximately 6-minute rsfMRI time series scan. Distributed measures of functional connectivity were calculated as the mean Pearson correlation between the average low-frequency time courses in predefined sets of regions of interest (ROI) within the default mode network (DMN), salience network (SN) and sensorimotor networks (SMN). LS mean value was controlled for baseline value and visit.</description>
          <population>All participants who enrolled in the study and had an evaluable MRI at the designated time point.</population>
          <units>arbitrary units (au)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anterior DMN - 6 Mos (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.017" lower_limit="-0.033" upper_limit="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior DMN - 12 Mos (n=28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.031" lower_limit="-0.017" upper_limit="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior SN - 6 Mos (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.012" lower_limit="-0.043" upper_limit="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior SN -12 Mos (n=28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.025" lower_limit="-0.065" upper_limit="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMN - 6 Mos (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.029" lower_limit="-0.060" upper_limit="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMN - 12 Mos (n=28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.031" lower_limit="-0.061" upper_limit="-0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior DMN - 6 Mos (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.061" lower_limit="-0.120" upper_limit="-0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior DMN - 12 Mos (n=28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.058" lower_limit="-0.096" upper_limit="-0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior SN - 6 Mos (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.012" lower_limit="-0.045" upper_limit="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior SN - 12 Mos (n=28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" lower_limit="-0.040" upper_limit="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SN - 6 Mos (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.021" lower_limit="-0.048" upper_limit="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SN - 12 Mos (n=28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" lower_limit="-0.043" upper_limit="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMN - 6 Mos (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.041" lower_limit="0.009" upper_limit="0.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMN - 12 Mos (n=28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.013" lower_limit="-0.060" upper_limit="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA)</title>
        <description>DTI scans used FA to measure water diffusion directionality in selected white matter (WM) tracts. ROI: Corpus collosum (CC), internal capsule (IC), posterior cingulum bundle (PCB), temporal white matter (TWM), uncinate fasciculus (UF), superior longitudinal fasciculus (SLF). LS mean value was controlled for baseline value and visit.</description>
        <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
        <population>All participants who enrolled in the study and had an evaluable MRI at the designated time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Participants with prodromal to mild AD underwent a florbetapir F 18 PET scan. (Single intravenous microdose of 260 to 370 MBq [7 to 10 mCi] of florbetapir.) Those who tested amyloid positive and met other disease diagnostic criteria received standard of care for up to 12 mos. No therapeutic investigational drug intended to treat AD was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA)</title>
          <description>DTI scans used FA to measure water diffusion directionality in selected white matter (WM) tracts. ROI: Corpus collosum (CC), internal capsule (IC), posterior cingulum bundle (PCB), temporal white matter (TWM), uncinate fasciculus (UF), superior longitudinal fasciculus (SLF). LS mean value was controlled for baseline value and visit.</description>
          <population>All participants who enrolled in the study and had an evaluable MRI at the designated time point.</population>
          <units>au</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean FA, CC (Genu) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.024" lower_limit="-0.046" upper_limit="-0.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, CC (Genu) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.021" lower_limit="-0.041" upper_limit="-0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, CC (Splenium) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.016" lower_limit="-0.043" upper_limit="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, CC (Splenium) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.009" lower_limit="-0.026" upper_limit="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, IC (Left) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.043" lower_limit="-0.066" upper_limit="-0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, IC (Left) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" lower_limit="-0.043" upper_limit="0.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, IC (Right) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.046" lower_limit="-0.067" upper_limit="-0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, IC (Right) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" lower_limit="-0.038" upper_limit="-0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, PCB (Left) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-0.012" upper_limit="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, PCB (Left) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" lower_limit="0.003" upper_limit="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, PCB (Right) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" lower_limit="-0.001" upper_limit="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, PCB (Right) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" lower_limit="-0.008" upper_limit="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, TWM (Left) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.017" lower_limit="-0.028" upper_limit="-0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, TWM (Left) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.011" lower_limit="-0.022" upper_limit="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, TWM (Right) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.014" lower_limit="-0.022" upper_limit="-0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, TWM (Right) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.009" lower_limit="-0.019" upper_limit="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, UF (Left) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.027" lower_limit="-0.045" upper_limit="-0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, UF (Left) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" lower_limit="-0.007" upper_limit="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, UF (Right) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.032" lower_limit="-0.049" upper_limit="-0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, UF (Right) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" lower_limit="-0.009" upper_limit="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, SLF (Left) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.014" lower_limit="-0.025" upper_limit="-0.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, SLF (Left) - 12 Mos (n=304)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" lower_limit="-0.014" upper_limit="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, SLF (Right) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" lower_limit="-0.019" upper_limit="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean FA, SLF (Right) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" lower_limit="-0.009" upper_limit="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD)</title>
        <description>DTI scans used MD to measure the overall magnitude of water diffusion in selected WM tracts, without specific regard to directionality. ROI: CC, IC, PCB, TWM, UF, SLF. LS mean value was controlled for baseline value and visit.</description>
        <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
        <population>All participants who enrolled in the study and had an evaluable MRI at the designated time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Participants with prodromal to mild AD underwent a florbetapir F 18 PET scan. (Single intravenous microdose of 260 to 370 MBq [7 to 10 mCi] of florbetapir.) Those who tested amyloid positive and met other disease diagnostic criteria received standard of care for up to 12 mos. No therapeutic investigational drug intended to treat AD was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD)</title>
          <description>DTI scans used MD to measure the overall magnitude of water diffusion in selected WM tracts, without specific regard to directionality. ROI: CC, IC, PCB, TWM, UF, SLF. LS mean value was controlled for baseline value and visit.</description>
          <population>All participants who enrolled in the study and had an evaluable MRI at the designated time point.</population>
          <units>square meters per second (m²/sec) * 10¹⁰</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean MD, CC (Genu) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.201" lower_limit="-0.157" upper_limit="0.559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD, CC (Genu) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.761" lower_limit="-0.280" upper_limit="1.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD, CC (Splenium) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.663" lower_limit="-0.114" upper_limit="1.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD, CC (Splenium) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.519" lower_limit="-0.956" upper_limit="-0.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD, IC (Left) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.410" lower_limit="0.043" upper_limit="0.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD, IC (Left) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.164" lower_limit="-0.107" upper_limit="0.435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD, IC (Right) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.441" lower_limit="0.203" upper_limit="0.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD, IC (Right) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.280" lower_limit="0.120" upper_limit="0.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD, PCB (Left) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.062" lower_limit="-0.326" upper_limit="0.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD, PCB (Left) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.175" lower_limit="-0.087" upper_limit="0.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD, PCB (Right) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.114" lower_limit="-0.156" upper_limit="0.385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD, PCB (Right) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.297" lower_limit="0.053" upper_limit="0.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD TWM (Left) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.014" lower_limit="-0.280" upper_limit="0.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD TWM (Left) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" lower_limit="-0.295" upper_limit="0.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD TWM (Right) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.243" lower_limit="-0.047" upper_limit="0.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD TWM (Right) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.285" lower_limit="0.077" upper_limit="0.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD, UF (Left) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.150" lower_limit="-0.518" upper_limit="0.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD, UF (Left) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.600" lower_limit="-1.005" upper_limit="-0.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD, UF (Right) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.240" lower_limit="-0.200" upper_limit="0.681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD, UF (Right) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.289" lower_limit="-0.649" upper_limit="0.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD SLF (Left) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.083" lower_limit="-0.070" upper_limit="0.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD SLF (Left) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" lower_limit="-0.108" upper_limit="0.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD SLF (Right) - 6 Mos (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.085" lower_limit="-0.113" upper_limit="0.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean MD SLF (Right) - 12 Mos (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.097" lower_limit="-0.004" upper_limit="0.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Brain Amyloid Load Using Positron Emission Tomography (PET) and Florbetapir</title>
        <description>Composite summary standardized uptake value ratio (SUVR) normalized to mean whole cerebellum. Regions used for composite summary were posterior cingulum, anterior cingulum, parietal cortex, lateral temporal cortex and frontal cortex.</description>
        <time_frame>Baseline</time_frame>
        <population>All participants with an amyloid positive florbetapir F 18 PET scan at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Participants with prodromal to mild AD underwent a florbetapir F 18 PET scan. (Single intravenous microdose of 260 to 370 MBq [7 to 10 mCi] of florbetapir.) Those who tested amyloid positive and met other disease diagnostic criteria received standard of care for up to 12 mos. No therapeutic investigational drug intended to treat AD was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Brain Amyloid Load Using Positron Emission Tomography (PET) and Florbetapir</title>
          <description>Composite summary standardized uptake value ratio (SUVR) normalized to mean whole cerebellum. Regions used for composite summary were posterior cingulum, anterior cingulum, parietal cortex, lateral temporal cortex and frontal cortex.</description>
          <population>All participants with an amyloid positive florbetapir F 18 PET scan at baseline.</population>
          <units>SUVR unit 1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.581" spread="0.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Vasogenic Edema on MRI Scan at a Field Strength of 3 Tesla (3T)</title>
        <time_frame>Baseline</time_frame>
        <population>All participants who had an MRI during screening and were classified as screen failures.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Participants with prodromal to mild AD underwent a florbetapir F 18 PET scan. (Single intravenous microdose of 260 to 370 MBq [7 to 10 mCi] of florbetapir.) Those who tested amyloid positive and met other disease diagnostic criteria received standard of care for up to 12 mos. No therapeutic investigational drug intended to treat AD was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vasogenic Edema on MRI Scan at a Field Strength of 3 Tesla (3T)</title>
          <population>All participants who had an MRI during screening and were classified as screen failures.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Microhemorrhage on MRI Scan at a Field Strength of 3T</title>
        <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
        <population>All participants who enrolled in the study and had an evaluable MRI at the designated time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Participants with prodromal to mild AD underwent a florbetapir F 18 PET scan. (Single intravenous microdose of 260 to 370 MBq [7 to 10 mCi] of florbetapir.) Those who tested amyloid positive and met other disease diagnostic criteria received standard of care for up to 12 mos. No therapeutic investigational drug intended to treat AD was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Microhemorrhage on MRI Scan at a Field Strength of 3T</title>
          <population>All participants who enrolled in the study and had an evaluable MRI at the designated time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Mos (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Mos (n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mini Mental State Examination (MMSE) Total Score</title>
        <description>The MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30; lower score indicates greater disease severity. LS mean value was controlled for baseline value and visit.</description>
        <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
        <population>All participants who enrolled in the study and completed the scale at the designated time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Participants with prodromal to mild AD underwent a florbetapir F 18 PET scan. (Single intravenous microdose of 260 to 370 MBq [7 to 10 mCi] of florbetapir.) Those who tested amyloid positive and met other disease diagnostic criteria received standard of care for up to 12 mos. No therapeutic investigational drug intended to treat AD was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mini Mental State Examination (MMSE) Total Score</title>
          <description>The MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30; lower score indicates greater disease severity. LS mean value was controlled for baseline value and visit.</description>
          <population>All participants who enrolled in the study and completed the scale at the designated time point.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Mos (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-2.0" upper_limit="-0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Mos (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" lower_limit="-2.7" upper_limit="-0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Alzheimer’s Disease Assessment Scale Extended Cognitive Subscale (ADAS-Cog14) Total Score</title>
        <description>The ADAS-Cog14 is the ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. LS mean value was controlled for baseline value and visit.</description>
        <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
        <population>All participants who enrolled in the study and completed the scale at the designated time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Participants with prodromal to mild AD underwent a florbetapir F 18 PET scan. (Single intravenous microdose of 260 to 370 MBq [7 to 10 mCi] of florbetapir.) Those who tested amyloid positive and met other disease diagnostic criteria received standard of care for up to 12 mos. No therapeutic investigational drug intended to treat AD was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Alzheimer’s Disease Assessment Scale Extended Cognitive Subscale (ADAS-Cog14) Total Score</title>
          <description>The ADAS-Cog14 is the ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. LS mean value was controlled for baseline value and visit.</description>
          <population>All participants who enrolled in the study and completed the scale at the designated time point.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Mos (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-1.6" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Mos (n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="-1.7" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Clinical Dementia Rating (CDR) Total Score</title>
        <description>The CDR is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score ranges from 0 to 18. Higher scores indicate greater disease severity. LS mean value was controlled for baseline value and visit.</description>
        <time_frame>Baseline, 6 Mos; Baseline, 12 Mos</time_frame>
        <population>All participants who enrolled in the study and completed the scale at the designated time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Participants with prodromal to mild AD underwent a florbetapir F 18 PET scan. (Single intravenous microdose of 260 to 370 MBq [7 to 10 mCi] of florbetapir.) Those who tested amyloid positive and met other disease diagnostic criteria received standard of care for up to 12 mos. No therapeutic investigational drug intended to treat AD was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Clinical Dementia Rating (CDR) Total Score</title>
          <description>The CDR is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score ranges from 0 to 18. Higher scores indicate greater disease severity. LS mean value was controlled for baseline value and visit.</description>
          <population>All participants who enrolled in the study and completed the scale at the designated time point.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Mos (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Mos (n=33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard of Care</title>
          <description>Participants with prodromal to mild AD underwent a florbetapir F 18 PET scan. (Single intravenous microdose of 260 to 370 MBq [7 to 10 mCi] of florbetapir.) Those who tested amyloid positive and met other disease diagnostic criteria received standard of care for up to 12 mos. No therapeutic investigational drug intended to treat AD was administered.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dementia alzheimer's type</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dementia alzheimer's type</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

